Philips and Yale expand research deal

Royal Philips (NYSE:PHG) said today it expanded its master research agreement with Yale School of Medicine to include a new research program looking to develop innovations in interventional oncology. The multi-year cancer research program aims to explore new concepts in image-guided therapies, diagnostic imaging and informatics, Philips said, and will engage with multiple research groups at Yale. “Over the past few years there have been significant developments in image-guided therapy to locally treat tumors, with the result that interventional oncology procedure volumes have grown rapidly. However, the biggest remaining challenge is that it is difficult to predict the effectiveness of the procedure. Together with Philips, we are embarking on a new multi-year research program with the aim to redefine and standardize this type of minimally-invasive treatment to achieve more predictable and better controlled procedure outcomes, and ultimately enhanced patient care,” research program lead Jeff Geschwind said in a press release. A team of clinical scientists from Philips will operate with Geschwild’s team at Yale in a recently established facility seeking to shift research results into innovations for patient care, the company said. “We are on a mission to enhance existing interventional oncology procedures and enable new ones that offer predictable and effective minimally invasive options for treating cancerous lesions. Our new collaboration wit...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Business/Financial News Diagnostics Oncology Research & Development Royal Philips Source Type: news

Related Links:

Abstract The field of cancer immunology stepped into the limelight this year when James P. Allison and Tasuku Honjo received the Nobel Prize in Physiology or Medicine for their discovery of cancer therapy by inhibition of negative immune regulation. Among many exciting advances contributing to the coming of age of tumour immunology as a viable clinical specialty has been the ability to progress from the initial elucidation of tumour antigens, such as the melanoma antigen, MAGE-1, to high-throughput sequencing facilitating identification of T cell epitopes from diverse tumour neoantigens. This has resulted from the...
Source: Immunology - Category: Allergy & Immunology Authors: Tags: Immunology Source Type: research
AbstractPurposeThis observational study was designed to measure baseline energy parameters and body composition in early-stage breast cancer patients, and to follow changes during and after various modalities of treatment. This will provide information to aid in the development of individualized physical activity intervention strategies.MethodsPatients with newly diagnosed stage 0 –III breast cancer were enrolled into three cohorts: A (local therapy alone), B (endocrine therapy), or C (chemotherapy with or without endocrine therapy). At baseline, 6 months, and 12 months, subjects underwent a stationary bicy...
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
Malignant pleural mesothelioma (MPM) is a rare tumor principally due to past exposure to asbestos, a carcinogenic natural mineral fiber that induces genomic and genetic alterations [1]. Lack of curative treatment due to resistance to anti-cancer therapies combined with tumor aggressiveness accounts for the poor prognosis associated to MPM. Despite the significant advances in oncotherapy, MPM is still a challenging cancer to treat [2].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Source: BMJ Comments - Category: General Medicine Source Type: forums
Fragile histidine triad (FHIT) serves a critical function as a tumor suppressor that inhibits p53 degradation by mouse double minute 2 (MDM2). The functional domains of FHIT involved in tumor inhibition was interpreted. In-silico screening data were employed to construct truncated forms of FHIT to assess their cytotoxic effects on the HT1080 cell line. Full FHIT expression was confirmed by western blotting and expression of two FHIT truncates were confirmed by RT-PCR. Transfection of these truncated forms into HT1080 cells showed that the N-terminal truncated form (amino acids 17-102) better inhibited proliferation than t...
Source: Iranian Journal of Pharmaceutical Research - Category: Drugs & Pharmacology Source Type: research
I think it is entirely appropriate to greet the advent of senolytics with enthusiasm. These treatments are the first legitimate rejuvenation therapies to successfully target one of the root causes of aging, the accumulation of lingering senescent cells in old tissues. The first human trial data is approaching publication, but even before it arrives, the evidence to date strongly suggests that meaningful levels of rejuvenation can be achieved in old people at a very low cost. The first senolytic drugs (such as dasatinib and navitoclax) and plant extracts (such as fisetin and piperlongumine) cost very little, and remove only...
Source: Fight Aging! - Category: Research Authors: Tags: Daily News Source Type: blogs
Substitutable Medical Apps, Reusable Technologies (SMART) apps have been developed to meet the need for responsiveness in healthcare IT. In this video, Stefanie Krens, MSc, of Radboud University Medic... Author: VJOncology Added: 10/15/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
Sangram Raut, Linda Mooberry, Nirupama Sabnis, Ashwini Garud, Akpedje Serena Dossou, Andras Lacko
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
CONCLUSIONS: Compared to ADT alone, the early (within 120 days of beginning ADT) addition of taxane-based chemotherapy to ADT for hormone-sensitive prostate cancer probably prolongs both overall and disease-specific survival and delays disease progression. There may be an increase in toxicity with taxane-based chemotherapy in combination with ADT. There may also be a small, clinically unimportant improvement in quality of life at 12 months with taxane-based chemotherapy and ADT treatment. PMID: 30320443 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Tags: Cochrane Database Syst Rev Source Type: research
Authors: Botti G, Cantile M PMID: 30303033 [PubMed - as supplied by publisher]
Source: Expert Review of Anticancer Therapy - Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Liver | Medical Devices | Urology & Nephrology | Yale